<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">PY7KxMBmx6RFw6JXR7xYhts</article-id>
      <article-id pub-id-type="other">00017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009001100017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300517</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009001100017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Uso cr&#244;nico de anticoagulante oral: implica&#231;&#245;es para o controle de n&#237;veis adequados</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Esmerio</surname>
            <given-names>Francieli Giachini</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Emiliane Nogueira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leiria</surname>
            <given-names>Tiago Luz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lunelli</surname>
            <given-names>Rosana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moraes</surname>
            <given-names>Maria Antonieta</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Universit&#225;ria de Cardiologia</institution>
        <institution content-type="orgdiv1">Instituto de Cardiologia do Rio Grande do Sul </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>11</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>5</issue>
      <fpage>549</fpage>
      <lpage>554</lpage>
      <history>
        <date date-type="accepted">
          <day>25</day>
          <month>06</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>19</day>
          <month>12</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>05</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Dosagens inapropriadas e subterap&#234;uticas anticoagulantes podem resultar em s&#233;rias complica&#231;&#245;es tromboemb&#243;licas. O uso dessa terap&#234;utica requer especial aten&#231;&#227;o e precisa de um acompanhamento cl&#237;nico e laboratorial rigoroso. OBJETIVO: Identificar fatores associados ao controle adequado dos n&#237;veis de anticoagula&#231;&#227;o oral, verificando o conhecimento e a percep&#231;&#227;o dos pacientes relacionados &#224; terap&#234;utica empregada. M&#201;TODOS: Estudo transversal que incluiu 140 pacientes acompanhados no ambulat&#243;rio de anticoagula&#231;&#227;o oral, de novembro de 2005 a junho de 2006. Um question&#225;rio estruturado foi elaborado e aplicado para obten&#231;&#227;o de caracter&#237;sticas cl&#237;nicas, conhecimento sobre a terap&#234;utica, ades&#227;o ao tratamento (teste de Morisky) e percep&#231;&#227;o do paciente. RESULTADOS: As principais indica&#231;&#245;es para uso do anticoagula&#231;&#227;o oral foram fibrila&#231;&#227;o atrial (61,4%) e pr&#243;tese met&#225;lica (55%). O tempo de uso variou entre 24 e 72 meses, e o femprocumona (58%) foi o mais empregado. Em rela&#231;&#227;o&#224; percep&#231;&#227;o da terap&#234;utica, 95% dos pacientes mencionaram preocupa&#231;&#227;o com o uso di&#225;rio dessa medica&#231;&#227;o. A realiza&#231;&#227;o peri&#243;dica de exames de sangue (21,4%) e a tomada rigorosa de anticoagula&#231;&#227;o oral (12,8%) foram compreendidas como limitantes. Observou-se conhecimento adequado entre os pacientes com international normalized ratio (INR) fora da faixa (64%) e na ader&#234;ncia entre os pacientes com INR dentro da faixa terap&#234;utica (54%), por&#233;m sem signific&#226;ncia estat&#237;stica. CONCLUS&#195;O: Os resultados deste estudo demonstraram uma preval&#234;ncia de pacientes em uso de anticoagula&#231;&#227;o oral com o INR dentro dos valores ideais, embora tenha sido grande a porcentagem de pacientes n&#227;o-aderentes &#224; terap&#234;utica. O conhecimento insatisfat&#243;rio quanto &#224; terap&#234;utica empregada e ao autocuidado torna-se evidente nessa popula&#231;&#227;o.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Anticoagulantes</kwd>
        <kwd>uso de medicamentos</kwd>
        <kwd>controle de medicamentos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>11</day>
        <month>01</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> TERAPIA INTENSIVA CARDIOL&#211;GICA</p>
    <p>Uso cr&#244;nico de anticoagulante oral: implica&#231;&#245;es para o controle de n&#237;veis adequados </p>
    <p>
      <bold>Francieli Giachini Esmerio; Emiliane Nogueira Souza; Tiago Luz Leiria; Rosana Lunelli; Maria Antonieta Moraes</bold>
    </p>
    <p> Instituto de Cardiologia do Rio Grande do Sul, da Funda&#231;&#227;o Universit&#225;ria de Cardiologia (IC/FUC), Porto Alegre, RS - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> Dosagens inapropriadas e subterap&#234;uticas anticoagulantes podem resultar em s&#233;rias complica&#231;&#245;es tromboemb&#243;licas. O uso dessa terap&#234;utica requer especial aten&#231;&#227;o e precisa de um acompanhamento cl&#237;nico e laboratorial rigoroso. </p>
    <p><bold>OBJETIVO:</bold> Identificar fatores associados ao controle adequado dos n&#237;veis de anticoagula&#231;&#227;o oral, verificando o conhecimento e a percep&#231;&#227;o dos pacientes relacionados &#224; terap&#234;utica empregada. </p>
    <p><bold>M&#201;TODOS:</bold> Estudo transversal que incluiu 140 pacientes acompanhados no ambulat&#243;rio de anticoagula&#231;&#227;o oral, de novembro de 2005 a junho de 2006. Um question&#225;rio estruturado foi elaborado e aplicado para obten&#231;&#227;o de caracter&#237;sticas cl&#237;nicas, conhecimento sobre a terap&#234;utica, ades&#227;o ao tratamento (teste de Morisky) e percep&#231;&#227;o do paciente. </p>
    <p><bold>RESULTADOS:</bold> As principais indica&#231;&#245;es para uso do anticoagula&#231;&#227;o oral foram fibrila&#231;&#227;o atrial (61,4%) e pr&#243;tese met&#225;lica (55%). O tempo de uso variou entre 24 e 72 meses, e o femprocumona (58%) foi o mais empregado. Em rela&#231;&#227;o&#224; percep&#231;&#227;o da terap&#234;utica, 95% dos pacientes mencionaram preocupa&#231;&#227;o com o uso di&#225;rio dessa medica&#231;&#227;o. A realiza&#231;&#227;o peri&#243;dica de exames de sangue (21,4%) e a tomada rigorosa de anticoagula&#231;&#227;o oral (12,8%) foram compreendidas como limitantes. Observou-se conhecimento adequado entre os pacientes com <italic>international normalized ratio</italic> (INR) fora da faixa (64%) e na ader&#234;ncia entre os pacientes com INR dentro da faixa terap&#234;utica (54%), por&#233;m sem signific&#226;ncia estat&#237;stica. </p>
    <p><bold>CONCLUS&#195;O:</bold> Os resultados deste estudo demonstraram uma preval&#234;ncia de pacientes em uso de anticoagula&#231;&#227;o oral com o INR dentro dos valores ideais, embora tenha sido grande a porcentagem de pacientes n&#227;o-aderentes &#224; terap&#234;utica. O conhecimento insatisfat&#243;rio quanto &#224; terap&#234;utica empregada e ao autocuidado torna-se evidente nessa popula&#231;&#227;o.</p>
    <p><bold>Palavras-chave:</bold> Anticoagulantes, uso de medicamentos, controle de medicamentos.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p> Embora o uso do anticoagulante oral seja efetivo, existem riscos associados, e as estimativas anuais est&#227;o entre 2% e 8% para risco de sangramento e 1%-3% na falha do tratamento. Isso torna importante decidir o momento adequado em que o paciente dever&#225; iniciar o tratamento ou modificar a dosagem da terapia medicamentosa<sup>1</sup>. O uso dessas drogas exige um controle especial em raz&#227;o das complica&#231;&#245;es hemorr&#225;gicas, o que torna imprescind&#237;vel um acompanhamento cl&#237;nico e laboratorial rigoroso por meio da avalia&#231;&#227;o da equipe multidisciplinar. A terapia medicamentosa com anticoagulante oral &#233; considerada fator de seguran&#231;a para o paciente, sendo necess&#225;ria uma maior aten&#231;&#227;o &#224; quest&#227;o de ades&#227;o &#224; medica&#231;&#227;o por parte dos profissionais de sa&#250;de. A baixa ades&#227;o aos medicamentos prescritos e conseq&#252;entemente ao tratamento cl&#237;nico proposto gera impactos negativos sobre todos os aspectos dos cuidados &#224; sa&#250;de, custos excessivos e subutiliza&#231;&#227;o dos recursos de tratamento dispon&#237;veis, al&#233;m de s&#233;rias conseq&#252;&#234;ncias aos pacientes e um aumento de eventos negativos nas doen&#231;as cr&#244;nicas.</p>
    <p>Em seus estudos, Sawicki<sup>2</sup> e Newall e cols.<sup>3</sup> descrevem um programa de orienta&#231;&#227;o para pacientes a respeito do pr&#243;prio ajuste e manejo do anticoagulante oral, em que o risco de qualquer complica&#231;&#227;o depender&#225; do tempo em que o medicamento &#233; utilizado e da seriedade do controle de INR, por meio de exames laboratoriais freq&#252;entes, para ajuste das doses. Samsa e cols.<sup>4</sup> e Hirsh e cols.<sup>5</sup> refor&#231;am que, para um paciente portador de v&#225;lvula mec&#226;nica, manter a anticoagula&#231;&#227;o em longo prazo significa aderir a um regime medicamentoso para o restante de sua vida.</p>
    <p>Alguns estudos<sup>6-8</sup> t&#234;m mostrado fatores que interferem no controle dos n&#237;veis de anticoagula&#231;&#227;o, incluindo fatores socioecon&#244;micos, fisiol&#243;gicos, psicol&#243;gicos e emocionais.</p>
    <p>Segundo a Organiza&#231;&#227;o Mundial da Sa&#250;de<sup>9</sup>, a baixa ader&#234;ncia aos medicamentos comp&#245;e hoje um grande desafio para a melhora das condi&#231;&#245;es de sa&#250;de em &#226;mbito mundial. Essas conclus&#245;es demonstram uma necessidade de maior esclarecimento sobre a utiliza&#231;&#227;o das drogas por parte da equipe para esse grupo de pacientes. Nesse contexto, este estudo teve por objetivo identificar fatores associados ao controle adequado dos n&#237;veis de anticoagulante oral, verificando o conhecimento e a percep&#231;&#227;o dos pacientes no que se refere &#224; terap&#234;utica empregada.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p> Trata-se de um estudo transversal, com pacientes acompanhados no ambulat&#243;rio de anticoagula&#231;&#227;o oral, de um hospital especializado em cardiologia no Rio Grande do Sul, no per&#237;odo de novembro de 2005 a junho de 2006. No ambulat&#243;rio de anticoagulante oral, os pacientes realizaram controles laboratoriais regulares de INR, sendo atendidos cerca de 1.200 pacientes/m&#234;s. Foram eleg&#237;veis para o estudo pacientes <underline>&gt;</underline> de 18 anos, em uso de anticoagulante oral e que aceitaram responder &#224;s quest&#245;es de pesquisa.</p>
    <p>Elaborou-se um question&#225;rio com quest&#245;es relacionadas aos seguintes aspectos: caracter&#237;sticas cl&#237;nicas e demogr&#225;ficas, ades&#227;o ao tratamento, conhecimento sobre a terap&#234;utica e percep&#231;&#227;o do paciente acerca do uso de anticoagulante oral. Para avaliar a ades&#227;o &#224; terap&#234;utica, foi utilizado o teste de Morisky<sup>7</sup>, que &#233; um instrumento validado e aplic&#225;vel nos diferentes tipos de terapia medicamentosa. Esse teste &#233; composto por quatro quest&#245;es objetivas como uma forma padronizada de medida, que avalia o comportamento do paciente ante o uso do medicamento prescrito. As quest&#245;es desse instrumento abordam hor&#225;rio, esquecimento, sintomas e efeitos colaterais. O teste de Morisky classifica como pacientes mais aderentes aqueles com maior n&#250;mero de acertos. Foram considerados INR dentro e fora dos n&#237;veis terap&#234;uticos preconizados, a m&#233;dia de cinco medidas/aferi&#231;&#245;es de INR de cada paciente. Para analisar o conhecimento dos pacientes quanto ao uso do anticoagulante, elaboraram-se duas quest&#245;es relacionadas ao objetivo da terap&#234;utica e ao principal efeito adverso. Foi considerado conhecimento adequado o acerto de ambas as quest&#245;es. Para identificar a percep&#231;&#227;o do paciente sobre o uso do anticoagulante oral, seis quest&#245;es foram pontuadas de modo a totalizarem um escore de 1 a 100 pontos, para o qual se atribuiu um n&#250;mero ordinal a cada resposta, iniciando com o n&#250;mero 1 para a resposta, que implica uma pior percep&#231;&#227;o sobre a terap&#234;utica.</p>
    <p>Para verificarmos as dificuldades na ader&#234;ncia &#224; terap&#234;utica preconizada, consideraram-se o relato verbal dos pacientes e a percep&#231;&#227;o do entrevistador. Foram considerados os aspectos socioecon&#244;micos, como idade, escolaridade, custos para transporte e medica&#231;&#245;es; aspectos fisiol&#243;gicos, como intera&#231;&#227;o entre medica&#231;&#245;es, uso de m&#250;ltiplas medica&#231;&#245;es, dieta com restri&#231;&#245;es, presen&#231;a de doen&#231;as associadas e limita&#231;&#227;o f&#237;sica para deslocamento; e aspectos emocionais, como nega&#231;&#227;o da doen&#231;a, hist&#243;rico de depress&#227;o, problemas de ordem pessoal e n&#237;vel cognitivo, que &#233; a capacidade do indiv&#237;duo em compreender, aplicar, analisar ou sintetizar sua condi&#231;&#227;o de sa&#250;de<sup>10</sup>.</p>
    <p>Este projeto foi aprovado pelo Comit&#234; de &#201;tica em Pesquisa da institui&#231;&#227;o, e todos os pacientes assinaram o termo de consentimento livre e esclarecido. As vari&#225;veis categ&#243;ricas foram descritas por meio de freq&#252;&#234;ncias absolutas e relativas, e as vari&#225;veis cont&#237;nuas foram descritas com m&#233;dia e desvio padr&#227;o ou mediana e intervalo interquartil&#237;co (percentis 25 e 75), conforme seguissem ou n&#227;o a distribui&#231;&#227;o normal. Para a compara&#231;&#227;o entre as vari&#225;veis categ&#243;ricas, utilizou-se o teste de &#967;&#178; de Pearson, com corre&#231;&#227;o de continuidade quando necess&#225;rio. Para comparar m&#233;dias entre grupos, foi utilizado o teste t de Student, conforme fossem respeitados ou n&#227;o os pressupostos param&#233;tricos. Utilizou-se um n&#237;vel de signific&#226;ncia de &#945; = 0,05.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Caracter&#237;sticas cl&#237;nicas e demogr&#225;ficas</bold>
    </p>
    <p> Foram inclu&#237;dos 140 pacientes em uso de anticoagulante oral, com idade m&#233;dia de 60 &#177; 11,5 anos. A principal indica&#231;&#227;o para o uso dessa terapia medicamentosa foi a fibrila&#231;&#227;o atrial (61,4%), seguida de pacientes portadores de pr&#243;tese met&#225;lica (55%). Os anticoagulantes utilizados por essa popula&#231;&#227;o foram o femprocumona (58%) e o varfarina (42%), variando entre 24 e 72 meses de uso. As comorbidades associadas mais prevalentes foram a hipertens&#227;o arterialsist&#234;mica (69,3%) e o diabetes melito (26,4%). Esses resultados est&#227;o expressos na <xref ref-type="table" rid="tab01">tabela 1</xref>.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt01.jpg"/></table-wrap>
    <p>
      <bold>Desempenho das quest&#245;es de percep&#231;&#227;o relacionada &#224; terap&#234;utica</bold>
    </p>
    <p> Para identificar a percep&#231;&#227;o do paciente sobre o uso do anticoagulante oral, seis quest&#245;es foram pontuadas de modo a totalizarem um escore de 0 a 100 pontos. Nossos resultados demonstraram que a m&#233;dia desse escore foi de 67,8 &#177; 12,8. Verificamos que 95% da amostra estudada mencionaram a preocupa&#231;&#227;o relacionada ao uso di&#225;rio dessa medica&#231;&#227;o, e 68,6% manifestaram inseguran&#231;a com a possibilidade de apresentar sangramentos. Nossos achados revelaram que a presen&#231;a de sangramentos ocorreu em 32,8% dos casos, sem eventos tromb&#243;ticos. As quest&#245;es referentes &#224; realiza&#231;&#227;o peri&#243;dica de exames de sangue e &#224; tomada rigorosa de anticoagulante oral foram compreendidas como limitantes com 21,4% e 12,8%, respectivamente. Esses resultados est&#227;o expressos na <xref ref-type="table" rid="tab02">tabela 2</xref>.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt02.jpg"/></table-wrap>
    <p>
      <bold>INR dentro e fora da faixa terap&#234;utica</bold>
    </p>
    <p> Ao compararmos os pacientes com INR dentro e fora dos n&#237;veis terap&#234;uticos preconizados, nossos achados mostraram que o conhecimento da terap&#234;utica e a ades&#227;o ao anticoagulante oral foram quase semelhantes entre os dois grupos. Houve uma discreta preval&#234;ncia de conhecimento adequado entre os pacientes com INR fora da faixa (64%) e na ader&#234;ncia entre os pacientes com INR dentro da faixa terap&#234;utica (54%), n&#227;o demonstrando diferen&#231;a estatisticamente significativa nesses resultados.</p>
    <p>Entre as principais indica&#231;&#245;es para o uso de anticoagulante, os pacientes portadores de fibril&#231;a&#231;&#227;o atrial prevaleceram com INR dentro da faixa terap&#234;utica, com tamb&#233;m predominaram os pacientes portadores de pr&#243;tese met&#225;lica com INR fora da faixa preconizada. Verificamos que houve um maior n&#250;mero de pacientes dentro da faixa terap&#234;utica em uso de femprocumona (62%) quando comparado com varfarina (38%). O n&#237;vel de cogni&#231;&#227;o (38,5%) e os aspectos emocionais e psicol&#243;gicos (69,2%) foram os fatores que mais contribu&#237;ram para dificultar a ader&#234;ncia dentro e fora da faixa, respectivamente. Os dados est&#227;o na <xref ref-type="table" rid="tab03">tabela 3</xref>.</p>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt03.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p> Nos &#250;ltimos anos, em cardiologia cl&#237;nica o uso de anticoagulantes orais teve sua indica&#231;&#227;o ampliada e validada por diversos estudos cl&#237;nicos<sup>11,12</sup>. Embora os anticoagulantes sejam clinicamente indicados para prevenir eventos tromboemb&#243;licos, dosagens inapropriadas e subterap&#234;uticas para manter o INR podem resultar em s&#233;rias complica&#231;&#245;es tromboemb&#243;licas. Pacientes que fazem uso dessa terap&#234;utica apresentam necessidades espec&#237;ficas, requerem especial aten&#231;&#227;o e, por isso, precisam de um acompanhamento cl&#237;nico e laboratorial rigoroso para avalia&#231;&#227;o da equipe de sa&#250;de.</p>
    <p>O presente estudo verificou que 64% e 54% dessa popula&#231;&#227;o atendida no ambulat&#243;rio de anticoagula&#231;&#227;o tiveram conhecimento adequado com INR fora da faixa e com INR dentro da faixa terap&#234;utica, respectivamente. Achados semelhantes foram descritos em um estudo que avaliou o impacto da ader&#234;ncia, do conhecimento e da qualidade de vida no controle do anticoagulante oral. Os resultados encontrados relatam que conhecimento sobre a terap&#234;utica n&#227;o est&#225; associado com controle adequado dos n&#237;veis de anticoagula&#231;&#227;o<sup>6</sup>, embora se esperasse o inverso, contudo nosso estudo confirmou esses achados. Um estudo atual de coorte prospectiva realizada em tr&#234;s clinicas especializadas da Pensilv&#226;nia, com intuito de determinar os efeitos da ader&#234;ncia sobre o controle da anticoagula&#231;&#227;o, demonstrou em seus achados que a baixa ader&#234;ncia &#233; potencialmente a origem do ineficiente controle da anticoagula&#231;&#227;o. Isso refor&#231;a que, mesmo os pacientes que receberam educa&#231;&#227;o sobre a import&#226;ncia da ades&#227;o &#224; terap&#234;utica, ainda apresentaram dificuldades em manter um bom controle da anticoagula&#231;&#227;o<sup>13</sup>.</p>
    <p>Um outro estudo retrospectivo realizado por Nakkar e cols.<sup>14</sup> avaliou o manejo com anticoagulante oral em 82 pacientes e evidenciou que a m&#233;dia de uso dessa terap&#234;utica foi de 17 anos. Da amostra estudada, 19,5% apresentaram, durante o tratamento, algum evento adverso, e 73% apresentaram INR fora da faixa terap&#234;utica, ressaltando a import&#226;ncia de programas de educa&#231;&#227;o para essa popula&#231;&#227;o de pacientes, bem como a necessidade de protocolos assistenciais para padronizar essa terap&#234;utica entre os profissionais de sa&#250;de. Manter essa terap&#234;utica em longo prazo &#233; uma dura tarefa tanto para a equipe de sa&#250;de como para o paciente. Insucessos tendem a elevar a morbidade e mortalidade, o que torna cada vez mais significativa a preocupa&#231;&#227;o com o manejo da terap&#234;utica empregada, que &#233; oneroso para o sistema p&#250;blico de sa&#250;de<sup>14,15</sup>.</p>
    <p>O anticoagulante mais empregado foi o femprocumona, com tempo m&#233;dio de uso entre 2 e 6 anos, sendo a fibrila&#231;&#227;o atrial a principal indica&#231;&#227;o. N&#227;o ocorreu nenhum evento tromb&#243;tico ou hemorr&#225;gico significativo.</p>
    <p>Ao avaliar a percep&#231;&#227;o dos pacientes rela&#231;&#227;o &#224; terap&#234;utica empregada, a m&#233;dia do escore foi de 67,8 &#177; 12,8. Verificamos que as principais preocupa&#231;&#245;es compreendidas como limitantes foram o uso di&#225;rio das medica&#231;&#245;es por um longo per&#237;odo de tempo, os efeitos adversos da droga e a necessidade de realiza&#231;&#227;o peri&#243;dica de exames de sangue; esses fatores podem contribuir para o abandono do tratamento. Dados semelhantes na literatura indicam que a dose &#250;nica ajuda a melhorar as taxas de ades&#227;o aos medicamentos<sup>16</sup>.</p>
    <p>De acordo com o estudo realizado por Grinberg<sup>17</sup>, com o prop&#243;sito de verificar estrat&#233;gias de ades&#227;o &#224; anticoagula&#231;&#227;o oral, o ineficaz entendimento sobre o tratamento proposto &#233; o principal respons&#225;vel pelo baixo controle de doen&#231;as cr&#244;nicas e eventos adversos, al&#233;m de condi&#231;&#245;es socioecon&#244;micas, tais como renda, escolaridade, custo com transporte e medica&#231;&#245;es que implicam a continuidade da terap&#234;utica.</p>
    <p>A fim de avaliar em que contexto das orienta&#231;&#245;es ocorrem mais defici&#234;ncias, dividimos as dificuldades de ader&#234;ncia em aspectos socioecon&#244;micos, n&#237;vel de cogni&#231;&#227;o, aspectos emocionais e fisiol&#243;gicos. Nossos achados demonstraram que a dificuldade de ader&#234;ncia encontrada nos pacientes dentro da faixa terap&#234;utica foi de 38,6% com rela&#231;&#227;o ao n&#237;vel de cogni&#231;&#227;o, e de 69,2% no que se refere aos aspectos emocionais e psicol&#243;gicos nos pacientes fora da faixa terap&#234;utica preconizada. Esses resultados sugerem que existem lacunas entre o que &#233; orientado aos pacientes e o que eles realmente absorvem de informa&#231;&#245;es.</p>
    <p>Vale lembrar que existem v&#225;rios m&#233;todos de aferi&#231;&#227;o da ades&#227;o ao tratamento medicamentoso, e todos eles com vantagens e desvantagens; nenhum deles &#233; considerado padr&#227;o-ouro. Dentre os m&#233;todos mais utilizados, destacam-se os classificados por alguns autores<sup>17</sup> como diretos e indiretos. Os m&#233;todos diretos baseiam-se em t&#233;cnicas anal&#237;ticas que verificam se o medicamento foi administrado na dose e na freq&#252;&#234;ncia necess&#225;rias, por meio de marcadores qu&#237;micos de maior perman&#234;ncia no organismo. A mensura&#231;&#227;o do n&#237;vel s&#233;rico da droga apresenta melhor acur&#225;cia, por&#233;m seu custo &#233; elevado, al&#233;m de ser um procedimento invasivo. O monitoramento eletr&#244;nico da abertura do inv&#243;lucro &#233; efetivo, mas seu custo tamb&#233;m &#233; alto. Os m&#233;todos indiretos incluem entrevistas estruturadas, doa&#231;&#245;es dos medicamentos para os pacientes e a contagem das p&#237;lulas que restaram nas consultas de retorno. Procedimentos muito utilizados em ensaios cl&#237;nicos, por&#233;m est&#227;o sujeito a manipula&#231;&#227;o pelo indiv&#237;duo, e tamb&#233;m n&#227;o inspiram fidedignidade.</p>
    <p>Pesquisas realizadas no mundo inteiro t&#234;m demonstrado a import&#226;ncia de pesquisas relacionadas &#224; ades&#227;o ao tratamento medicamentoso e &#224;s mudan&#231;as de estilos de vida dos pacientes em uso de anticoagulante oral. Autores ressaltam que a qualidade do controle terap&#234;utico para manter os n&#237;veis ideais de INR e a ades&#227;o &#224; terap&#234;utica &#233; baixa, por causa da car&#234;ncia e/ou das falhas nos protocolos existentes e em raz&#227;o da inexist&#234;ncia de equipes de sa&#250;de especializadas para realizar programas educacionais<sup>18,19</sup>. A compreens&#227;o de fatores determinantes da terap&#234;utica, como a correta forma de tomar as medica&#231;&#245;es, a preven&#231;&#227;o e identifica&#231;&#227;o dos principais eventos adversos e a intera&#231;&#227;o entre droga e dieta remetem ao sucesso do tratamento, possibilitam a ader&#234;ncia e o alcance dos n&#237;veis ideais de anticoagula&#231;&#227;o e reduzem a morbidade e mortalidade de pacientes com terapia em longo prazo<sup>3,20</sup>.</p>
    <p>O progn&#243;stico de pacientes em uso de anticoagulante oral depende n&#227;o apenas da terap&#234;utica farmacol&#243;gica, como tamb&#233;m de aspectos n&#227;o-farmacol&#243;gicos fundamentais para o tratamento. Os pacientes necessitam de acompanhamento constante para receber orienta&#231;&#245;es a respeito do autocuidado, da possibilidade de evento tromboemb&#243;lico e de maneiras de adapta&#231;&#227;o &#224; terap&#234;utica empregada. A educa&#231;&#227;o em sa&#250;de &#233; uma das atribui&#231;&#245;es das equipes que trabalham com essa popula&#231;&#227;o de pacientes, para isso se faz necess&#225;rio que os profissionais desenvolvam novas estrat&#233;gias visando melhorar a ades&#227;o &#224; terap&#234;utica.</p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p> Os resultados deste estudo n&#227;o demonstraram associa&#231;&#227;o entre as vari&#225;veis analisadas nos subgrupos dentro e fora da faixa terap&#234;utica, avaliada pelo INR. No entanto, apesar da preval&#234;ncia de pacientes em uso de anticoagulante oral com INR dentro dos valores preconizados, ainda h&#225; uma boa parte de pacientes n&#227;o-aderentes &#224; terap&#234;utica. O desenvolvimento de novas pesquisas, como estudos randomizados, com estrat&#233;gias sistem&#225;ticas de educa&#231;&#227;o acerca de medidas terap&#234;uticas n&#227;o-farmacol&#243;gicas, &#233; fundamental para buscar mais evid&#234;ncias sobre os problemas identificados e tamb&#233;m para o desenvolvimento de protocolos assistenciais que identifiquem a n&#227;o-ades&#227;o, no intuito de minimizar as complica&#231;&#245;es e preencher as lacunas referentes ao uso cont&#237;nuo de anticoagulante oral.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p> Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p> O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p> Este artigo &#233; parte de tese de Monografia de Resid&#234;ncia Integrada em sa&#250;de de Francieli Giachini Esm&#233;rio pelo Instituto de Cardiologia do Rio Grande do Sul / Funda&#231;&#227;o Universit&#225;ria de Cardiologia.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Maria Antonieta Moraes </p>
        <p> Rua Miguel Couto, 335/602 &#150; Menino Deus </p>
        <p> 90850-050 Porto Alegre, RS - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="antonieta_moraes@uol.com.br">antonieta_moraes@uol.com.br</email>, </p>
        <p>
          <email xlink:href="editoracao@cardiologia.org.br">editoracao@cardiologia.org.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 19/12/2007; revisado recebido em 06/05/2008; aceito em 25/06/2008. </p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Arnason T, Wells PS, Walraven C, Foster AJ.    Accuracy of coding for possible warfarin complications in hospital discharge    abstracts. Thromb Res. 2006; 118 (2):253-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Accuracy of coding for possible warfarin complications in hospital discharge abstracts</article-title>
          <source>Thromb Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>253</fpage>
          <lpage>62</lpage>
          <issue>2</issue>
          <volume>118</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arnason</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Walraven</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Sawicki PT. A structured teaching and self-management    program for patients for receiving oral anticoagulation: a randomized controlled    trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation.    JAMA. 1999; 281 (2): 145-50.</mixed-citation>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Sawicki</surname>
              <given-names>PT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Newall F, Monagle P, Johnston L. Home INR    monitoring of oral anticoagulant therapy in children using the CoaguCheck TM    S point-of-care monitor and a robust education program. Thromb Res. 2006; 118    (5): 587-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Home INR monitoring of oral anticoagulant therapy in children using the CoaguCheck TM S point-of-care monitor and a robust education program</article-title>
          <source>Thromb Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>587</fpage>
          <lpage>93</lpage>
          <issue>5</issue>
          <volume>118</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Newall</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Monagle</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Samsa G, Matchar DB, Dolor RJ, Wiklund I,    Hedner E, Wygant G, et al. A new instrument for measuring anticoagulation-related    quality of life: development and preliminary validation. Health Qual Life Outcome.    2004; 2: 22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation</article-title>
          <source>Health Qual Life Outcome</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>22</fpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Samsa</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Matchar</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Dolor</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Wiklund</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hedner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wygant</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Hirsh J, Fuster V, Ansell J, Halperin JL.    American Heart Association/ American College of Cardiology Foundation Guide    to warfarin therapy. J Am Coll Cardiol. 2003; 41 (9): 1633-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>American Heart Association/ American College of Cardiology Foundation Guide to warfarin therapy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1633</fpage>
          <lpage>52</lpage>
          <issue>9</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hirsh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ansell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Halperin</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Davis NJ, Billett HH, Cohen HW, ArnsAten    JH. Impact of adherence, knowledge, and quality of life on anticoagulation control.    Ann Pharmacother. 2005; 39: 632-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impact of adherence, knowledge, and quality of life on anticoagulation control</article-title>
          <source>Ann Pharmacother</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>632</fpage>
          <lpage>6</lpage>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Billett</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>ArnsAten</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Morisky DE, Green LW, Levine DM. Concurrent    and predictive validity of a self-reported measure of medication adherence.    Medical Care. 1986; 24: 67-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Concurrent and predictive validity of a self-reported measure of medication adherence</article-title>
          <source>Medical Care</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>67</fpage>
          <lpage>74</lpage>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morisky</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Yasaka M, Naritomi H, Minematsu K. Ischemic    stroke associate with brief cessation of warfarin. Thromb Res. 2006; 118 (2):    290-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ischemic stroke associate with brief cessation of warfarin</article-title>
          <source>Thromb Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>290</fpage>
          <lpage>3</lpage>
          <issue>2</issue>
          <volume>118</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yasaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Naritomi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Minematsu</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Adherence to long-term therapies. Evidence for action. World Health Organization. Geneva: Word Health Organization, 2003. [acesso em 2007 Mar 2]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/chp/knowledge/publications/adherencereport/en;index.html">http://www.who.int/chp/knowledge/publications/adherencereport/en;index.html</ext-link></mixed-citation>
        <element-citation publication-type="book">
          <source>Adherence to long-term therapies: Evidence for action</source>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Bloom BS, Engelhart MD, Furst EJ, Hill WH,    Krathwohl DR. Taxonomia de objetivos educacionais: dom&#237;nio cognitivo.    Porto Alegre: Globo, 1973.</mixed-citation>
        <element-citation publication-type="book">
          <source>Taxonomia de objetivos educacionais: dom&#237;nio cognitivo</source>
          <date>
            <year>1973</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Bloom</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Engelhart</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Furst</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Krathwohl</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Fredman MD. Oral anticoagulants: pharmacodynamics,    clinical indications and adverse effects. J Clin Pharmacol. 1992; 32 (3): 196-209.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects</article-title>
          <source>J Clin Pharmacol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>196</fpage>
          <lpage>209</lpage>
          <issue>3</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fredman</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Fihn SD, Gadisseur AA, Pasterkamp E; van    der Meer FJ, Breukink-Engbers WG, Geven-Boere LM, et al. Comparison of control    and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.    Thromb Haemost. 2003; 90 (2): 260-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon</article-title>
          <source>Thromb Haemost</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>260</fpage>
          <lpage>6</lpage>
          <issue>2</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fihn</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Gadisseur</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Pasterkamp</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van der Meer</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Breukink-Engbers</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Geven-Boere</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Kimmel SE, Chen Z, Price M, Parker CS, Metlay    NW, Christie JD, et al. The influence of patient adherence on anticoagulation    control with warfarin. Arch Intern Med. 2007; 167: 229-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The influence of patient adherence on anticoagulation control with warfarin</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>229</fpage>
          <lpage>35</lpage>
          <volume>167</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kimmel</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Metlay</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Christie</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Nakkar N, Kaur R, John M. Outpatient oral    anticoagulant management: an audit of 82 patients. J Assoc Physicians India.    2005; (53): 847-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outpatient oral anticoagulant management: an audit of 82 patients</article-title>
          <source>J Assoc Physicians India</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>847</fpage>
          <lpage>52</lpage>
          <issue>53</issue>
          <person-group person-group-type="author">
            <name>
              <surname>Nakkar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>John</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Sawicki PT, Gl&#228;ser B, Kleespies C,    Stubbe J, Schimitz N, Kaiser T, et al. Self-management of oral anticoagulation:    long-term results. J Intern Med. 2003; 254 (5): 515-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Self-management of oral anticoagulation: long-term results</article-title>
          <source>J Intern Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>515</fpage>
          <lpage>6</lpage>
          <issue>5</issue>
          <volume>254</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sawicki</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Gl&#228;ser</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kleespies</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stubbe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schimitz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Leite SN, Vasconcellos MPC. Ades&#227;o    &#224; terap&#234;utica medicamentosa: elementos para a discuss&#227;o    de conceitos e pressupostos adotados na literatura. Ci&#234;ncia Sa&#250;de    Coletiva. 2003; 8 (3): 775-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ades&#227;o &#224; terap&#234;utica medicamentosa: elementos para a discuss&#227;o de conceitos e pressupostos adotados na literatura</article-title>
          <source>Ci&#234;ncia Sa&#250;de Coletiva</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>775</fpage>
          <lpage>82</lpage>
          <issue>3</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Leite</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Vasconcellos</surname>
              <given-names>MPC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Grinberg M. Entendo, aceito, fa&#231;o:    estrat&#233;gia pr&#243;  ades&#227;o &#224; anticoagula&#231;&#227;o    oral. Arq Bras Cardiol. 2004; 82 (4): 309-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Entendo, aceito, fa&#231;o: estrat&#233;gia pr&#243; - ades&#227;o &#224; anticoagula&#231;&#227;o oral</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>309</fpage>
          <lpage>12</lpage>
          <issue>4</issue>
          <volume>82</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grinberg</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Yermiahu T, Arbelle JE, Shwartz D, Levy    Y, Tractinsky N, Porath A. Quality assessment of oral anticoagulant treatment    in Beer-Sheba district. Int J Qual Health Care. 2001; 13 (3): 209-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Quality assessment of oral anticoagulant treatment in Beer-Sheba district</article-title>
          <source>Int J Qual Health Care</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>209</fpage>
          <lpage>13</lpage>
          <issue>3</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yermiahu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arbelle</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Shwartz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tractinsky</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Porath</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Duarte PS, Ciconelli RM. Instrumento para    avalia&#231;&#227;o da qualidade de vida: gen&#233;ricos e espec&#237;ficos.    In: Diniz DP, Schor N. Guia de qualidade de vida. S&#227;o Paulo: Manole,    2006. p.11-8.</mixed-citation>
        <element-citation publication-type="book">
          <source>Guia de qualidade de vida</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>11</fpage>
          <lpage>8</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Duarte</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Ciconelli</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Diniz</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Schor</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Nakkar N, Kaur R. Knowledge base of clinicians    regarding oral anticoagulant therapy in a teaching institution: a questionnaire    survey. J Assoc Physicians India. 2004; (52): 868-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Knowledge base of clinicians regarding oral anticoagulant therapy in a teaching institution: a questionnaire survey</article-title>
          <source>J Assoc Physicians India</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>868</fpage>
          <lpage>72</lpage>
          <issue>52</issue>
          <person-group person-group-type="author">
            <name>
              <surname>Nakkar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Uso cr&#243;nico de anticoagulante oral implicaciones para el control de niveles adecuados</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: Dosis inapropiadas y subterap&#233;uticas anticoagulantes pueden resultar en serias complicaciones tromboemb&#243;licas. El uso de esta terap&#233;utica requiere especial atenci&#243;n y precisa un seguimiento cl&#237;nico y anal&#237;tico riguroso. OBJETIVO: Identificar factores asociados al control adecuado de los niveles de anticoagulaci&#243;n oral, verificando el conocimiento y la percepci&#243;n de los pacientes relacionados a la terap&#233;utica empleada. M&#201;TODOS: Estudio transversal que incluy&#243; a 140 pacientes seguidos en el ambulatorio de anticoagulaci&#243;n oral, desde noviembre de 2005 a junio de 2006. Se elabor&#243; y se aplic&#243; un cuestionario estructurado para la obtenci&#243;n de caracter&#237;sticas cl&#237;nicas, conocimiento sobre la terap&#233;utica, adhesi&#243;n al tratamiento (test de Morisky) y percepci&#243;n del paciente. RESULTADOS: Las principales indicaciones para uso de anticoagulaci&#243;n oral fueron fibrilaci&#243;n atrial (61,4%) y pr&#243;tesis met&#225;lica (55%). El tiempo de uso vari&#243; entre 24 y 72 meses, y el fenprocumona (58%) fue el m&#225;s empleado. Con relaci&#243;n a la percepci&#243;n de la terap&#233;utica, el 95% de los pacientes mencionaron preocupaci&#243;n con el uso diario de esta medicaci&#243;n. La realizaci&#243;n peri&#243;dica de an&#225;lisis de sangre (21,4%) y el tomar anticoagulaci&#243;n oral rigurosamente (12,8%) fueron comprendidos como limitantes. Se observ&#243; conocimiento adecuado entre los pacientes con international normalized ratio (INR) fuera del intervalo (64%) y en la adhesi&#243;n entre los pacientes con INR dentro del intervalo terap&#233;utico (54%), aunque sin significancia estad&#237;stica. CONCLUSI&#211;N: Los resultados de este estudio mostraron una prevalencia de pacientes en uso de anticoagulaci&#243;n oral con el INR dentro de los valores ideales, aunque haya sido grande el porcentaje de pacientes no adheridos a la terap&#233;utica. El conocimiento insatisfactorio con relaci&#243;n a la terap&#233;utica empleada y al autocuidado se vuelve evidente en esa poblaci&#243;n.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Anticoagulantes</kwd>
        <kwd>uso de medicamentos</kwd>
        <kwd>controle de medicamentos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="title-body2"/>Uso cr&#243;nico de anticoagulante oral implicaciones para el control de niveles adecuados </p>
      <p>
        <bold>Francieli Giachini Esmerio; Emiliane Nogueira Souza; Tiago Luz Leiria; Rosana Lunelli; Maria Antonieta Moraes</bold>
      </p>
      <p>Instituto de Cardiologia do Rio Grande do Sul, da Funda&#231;&#227;o Universit&#225;ria de Cardiologia (IC/FUC), Porto Alegre, RS - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold> FUNDAMENTO: </bold>Dosis inapropiadas y subterap&#233;uticas anticoagulantes pueden resultar en serias complicaciones tromboemb&#243;licas. El uso de esta terap&#233;utica requiere especial atenci&#243;n y precisa un seguimiento cl&#237;nico y anal&#237;tico riguroso.</p>
      <p><bold>OBJETIVO: </bold>Identificar factores asociados al control adecuado de los niveles de anticoagulaci&#243;n oral, verificando el conocimiento y la percepci&#243;n de los pacientes relacionados a la terap&#233;utica empleada.</p>
      <p><bold>M&#201;TODOS: </bold>Estudio transversal que incluy&#243; a 140 pacientes seguidos en el ambulatorio de anticoagulaci&#243;n oral, desde noviembre de 2005 a junio de 2006. Se elabor&#243; y se aplic&#243; un cuestionario estructurado para la obtenci&#243;n de caracter&#237;sticas cl&#237;nicas, conocimiento sobre la terap&#233;utica, adhesi&#243;n al tratamiento (test de Morisky) y percepci&#243;n del paciente.</p>
      <p><bold>RESULTADOS:</bold> Las principales indicaciones para uso de anticoagulaci&#243;n oral fueron fibrilaci&#243;n atrial (61,4%) y pr&#243;tesis met&#225;lica (55%). El tiempo de uso vari&#243; entre 24 y 72 meses, y el fenprocumona (58%) fue el m&#225;s empleado. Con relaci&#243;n a la percepci&#243;n de la terap&#233;utica, el 95% de los pacientes mencionaron preocupaci&#243;n con el uso diario de esta medicaci&#243;n. La realizaci&#243;n peri&#243;dica de an&#225;lisis de sangre (21,4%) y el tomar anticoagulaci&#243;n oral rigurosamente (12,8%) fueron comprendidos como limitantes. Se observ&#243; conocimiento adecuado entre los pacientes con international normalized ratio (INR) fuera del intervalo (64%) y en la adhesi&#243;n entre los pacientes con INR dentro del intervalo terap&#233;utico (54%), aunque sin significancia estad&#237;stica. </p>
      <p><bold>CONCLUSI&#211;N: </bold>Los resultados de este estudio mostraron una prevalencia de pacientes en uso de anticoagulaci&#243;n oral con el INR dentro de los valores ideales, aunque haya sido grande el porcentaje de pacientes no adheridos a la terap&#233;utica. El conocimiento insatisfactorio con relaci&#243;n a la terap&#233;utica empleada y al autocuidado se vuelve evidente en esa poblaci&#243;n.</p>
      <p><bold>Palabras clave:</bold> Anticoagulantes, uso de medicamentos, controle de medicamentos.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Aunque el uso del anticoagulante oral sea efectivo, hay riesgos asociados, y las estimativas anuales est&#225;n entre el 2% y el 8% para riesgo de hemorragia y el 1%-3% en la falla del tratamiento. Esto hace importante decidir el momento adecuado en que el paciente deber&#225; inicial el tratamiento o modificar la dosis de la terapia medicamentosa<sup>1</sup>. El uso de estas drogas exige un control especial en raz&#243;n de las complicaciones hemorr&#225;gicas, lo que hace imprescindible un seguimiento cl&#237;nico y anal&#237;tico riguroso por medio de la evaluaci&#243;n del equipo multidisciplinario. La terapia medicamentosa con anticoagulante oral est&#225; considerada factor de seguridad para el paciente, siendo necesaria una mayor atenci&#243;n al aspecto de adhesi&#243;n a la medicaci&#243;n por parte de los profesionales de salud. La baja adhesi&#243;n a los medicamentos prescriptos y por consiguiente al tratamiento cl&#237;nico propuesto genera impactos negativos sobre todos los aspectos de los cuidados a la salud, costos excesivos y subutilizaci&#243;n de los recursos de tratamiento disponibles, adem&#225;s de serias consecuencias para los pacientes y un aumento de eventos negativos en las enfermedades cr&#243;nicas. </p>
      <p>En sus estudios, Sawicki<sup>2 </sup>y Newall et al<sup>3</sup> describen un programa de orientaci&#243;n para pacientes a respecto del propio ajuste y manejo de la anticoagulaci&#243;n oral, en el cual el riesgo de cualquier complicaci&#243;n depender&#225; del tiempo en que el medicamento se utiliza y de la seriedad del control de INR, por medio de ex&#225;menes de laboratorio frecuentes, para ajuste de las dosis. Samsa et al.<sup>4 </sup>y Hirsh et al.<sup>5</sup> refuerzan que, para un paciente portador de v&#225;lvula mec&#225;nica, mantener la anticoagulaci&#243;n a largo plazo significa adherir a un r&#233;gimen medicamentoso para el resto de su vida. </p>
      <p>Algunos estudios<sup>6-8 </sup> han mostrado factores que interfieren en el control de los niveles de anticoagulaci&#243;n, incluyendo factores socioecon&#243;micos, fisiol&#243;gicos, psicol&#243;gicos y emocionales.</p>
      <p>De acuerdo con la Organizaci&#243;n Mundial de la Salud<sup>9</sup>, la baja adhesi&#243;n a los medicamentos constituye hoy un gran desaf&#237;o para la mejora de las condiciones de salud en &#225;mbito mundial. Estas conclusiones demuestran la necesidad de mayores aclaraciones sobre la utilizaci&#243;n de las drogas por parte del equipo para este grupo de pacientes. En este contexto, este estudio tuvo por objetivo identificar factores asociados al control adecuado de los niveles de anticoagulaci&#243;n oral, verificando el conocimiento y la percepci&#243;n de los pacientes en lo tocante a la terap&#233;utica empleada.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Se trata de un estudio transversal, con pacientes seguidos en el ambulatorio de anticoagulaci&#243;n oral, de un hospital especializado en cardiolog&#237;a en Rio Grande do Sul, en el per&#237;odo de noviembre de 2005 a junio de 2006. En el ambulatorio de anticoagulante oral, los pacientes realizaron controles de laboratorio regulares de INR, siendo atendidos cerca de 1.200 pacientes/mes. Fueron elegibles para el estudio pacientes &#8805; de 18 a&#241;os, en uso de anticoagulante oral y que aceptaron responder a las preguntas de la investigaci&#243;n.</p>
      <p>Se elabor&#243; un cuestionario con preguntas relacionadas a los siguientes aspectos: caracter&#237;sticas cl&#237;nicas y demogr&#225;ficas, adhesi&#243;n al tratamiento, conocimiento sobre la terap&#233;utica y percepci&#243;n del paciente acerca del uso de anticoagulante oral. Para evaluar la adhesi&#243;n a la terap&#233;utica, se utiliz&#243; el test de Morisky<sup>7</sup>, que es un instrumento validado y aplicable en los diferentes tipos de terapia medicamentosa. Este test se compone de cuatro preguntas objetivas como una forma normalizada de medida, que eval&#250;a el comportamiento del paciente frente al uso del medicamento prescripto. Las preguntas de este instrumento abordan horario, olvido, s&#237;ntomas y efectos colaterales. El test de Morisky clasifica como pacientes con mayor adhesi&#243;n a aquellos con mayor n&#250;mero de aciertos. Se consideraron INR dentro y fuera de los niveles terap&#233;uticos preconizados, el promedio de cinco medidas de INR de cada paciente. Para analizar el conocimiento de los pacientes en cuanto al uso del anticoagulante, se elaboraron dos preguntas relacionadas al objetivo de la terap&#233;utica y al principal efecto adverso. Se consider&#243; conocimiento adecuado el acierto de ambas preguntas. Para identificar la percepci&#243;n del paciente sobre el uso del anticoagulante oral, seis preguntas fueron calificadas de modo de totalizar un score de 1 a 100 puntos, para lo cual se atribuy&#243; un n&#250;mero ordinal a cada respuesta, iniciando con el n&#250;mero 1 para la respuesta, que implica una peor percepci&#243;n sobre la terap&#233;utica. </p>
      <p>Para verificar las dificultades en la adhesi&#243;n a la terap&#233;utica preconizada, se consideraron el relato verbal de los pacientes y la percepci&#243;n del entrevistador. Se consideraron los aspectos socioecon&#243;micos, como edad, escolaridad, costos para transporte y medicaciones, aspectos fisiol&#243;gicos, como interacci&#243;n entre medicaciones, uso de medicaciones m&#250;ltiples, dieta con restricciones, presencia de enfermedades asociadas y limitaci&#243;n f&#237;sica para desplazamiento, y aspectos emocionales, como negaci&#243;n de la enfermedad, historia de depresi&#243;n, problemas de orden personal y nivel cognitivo, que es la capacidad del individuo de comprender, aplicar, analizar o sintetizar su condici&#243;n de salud<sup>10</sup>. </p>
      <p>Este proyecto fue aprobado por el Comit&#233; de &#201;tica en Investigaci&#243;n de la instituci&#243;n y todos los pacientes firmaron el t&#233;rmino de consentimiento libre e informado. Las variables categ&#243;ricas se describieron por medio de frecuencias absolutas y relativas, y las variables continuas se describieron con promedio y desviaci&#243;n est&#225;ndar o mediana e intervalo intercuart&#237;lico (percentiles 25 y 75) conforme siguieran o no la distribuci&#243;n normal. Para la comparaci&#243;n entre las variables categ&#243;ricas, se utiliz&#243; el test &#967;&#178; de Pearson, con correcci&#243;n de continuidad cuando fue necesario. Para comparar los promedios entre grupos se utiliz&#243; el test t de Student, seg&#250;n se respetaran o no los presupuestos param&#233;tricos. Se utiliz&#243; un nivel de significancia &#945; = 0,05.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Caracter&#237;sticas cl&#237;nicas y demogr&#225;ficas</bold>
      </p>
      <p>Se incluyeron 140 pacientes en uso de anticoagulante oral, con edad promedio de 60 &#177; 11,5 a&#241;os. La principal indicaci&#243;n para el uso de esta terapia medicamentosa fue la fibrilaci&#243;n atrial (61,4%), seguida de pacientes portadores de pr&#243;tesis met&#225;lica (55%). Los anticoagulantes utilizados por esta poblaci&#243;n fueron la fenprocumona (58%) y la warfarina (42%), variando entre 24 y 72 meses de uso. Las comorbilidades asociadas m&#225;s prevalentes fueron la hipertensi&#243;n arterial sist&#233;mica (69,3%) y la diabetes mellitus (26,4%). Estos resultados se ilustran en la <xref ref-type="table" rid="tab01-body2">tabla 1</xref>.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Desempe&#241;o de las preguntas de percepci&#243;n relacionadas a la terap&#233;utica</bold>
      </p>
      <p>Para identificar la percepci&#243;n del paciente sobre el uso del anticoagulante oral, se calificaron seis preguntas de forma de totalizar un score de 0 a 100 puntos. Nuestros resultados mostraron que el promedio de ese score fue de 67,8 &#177; 12,8. Verificamos que el 95% de la muestra estudiada mencion&#243; la preocupaci&#243;n relacionada al uso diario de esa medicaci&#243;n, y el 68,6% manifest&#243; inseguridad con la posibilidad de presentar hemorragias. Nuestros hallazgos revelaron que la presencia de hemorragias ocurri&#243; en el 32,8% de los casos, sin eventos tromb&#243;ticos. Las cuestiones referentes a la realizaci&#243;n peri&#243;dica de ex&#225;menes de sangre y a tomar el anticoagulante oral rigurosamente fueron comprendidas como limitantes con el 21,4% y el 12,8%, respectivamente. Estos resultados se ilustran en la <xref ref-type="table" rid="tab02-body2">tabla 2</xref>. </p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>INR dentro y fuera del intervalo terap&#233;utico</bold>
      </p>
      <p>Al comparar los pacientes con INR dentro y fuera de los niveles terap&#233;uticos preconizados, nuestros hallazgos mostraron que el conocimiento de la terap&#233;utica y la adhesi&#243;n al anticoagulante oral fueron casi similares entre los dos grupos. Hubo una discreta prevalencia del conocimiento adecuado entre los pacientes con INR fuera del intervalo (64%) y en la adhesi&#243;n entre los pacientes con INR dentro del intervalo terap&#233;utico (54%), no demostrando diferencia estad&#237;sticamente significativa en esos resultados.</p>
      <p>Entre las principales indicaciones para el uso de anticoagulante, los pacientes portadores de fibrilaci&#243;n atrial prevalecieron con INR dentro del intervalo terap&#233;utico, como tambi&#233;n predominaron los pacientes portadores de pr&#243;tesis met&#225;lica con INR fuera del intervalo preconizado. Verificamos que hubo un mayor n&#250;mero de pacientes dentro del intervalo terap&#233;utico en uso de fenprocumona (62%) al compararlo con warfarina (38%). El nivel cognitivo (38,5%) y los aspectos emocionales y psicol&#243;gicos (69,2%) fueron los factores que m&#225;s contribuyeron para dificultar la adhesi&#243;n dentro y fuera del intervalo, respectivamente. Los datos est&#225;n en la <xref ref-type="table" rid="tab03-body2">tabla 3</xref>.</p>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt03-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n </bold>
      </p>
      <p>En los &#250;ltimos a&#241;os, en cardiolog&#237;a cl&#237;nica el uso de anticoagulantes orales tuvo su indicaci&#243;n ampliada y validada por diversos estudios cl&#237;nicos<sup>11,12</sup>. Aunque los anticoagulantes est&#233;n cl&#237;nicamente indicados para prevenir eventos tromboemb&#243;licos, dosis inapropiadas y subterap&#233;uticas para mantener el INR pueden resultar en serias complicaciones tromboemb&#243;licas. Pacientes que utilizan esta terap&#233;utica presentan necesidades espec&#237;ficas, requieren especial atenci&#243;n y, por ello, precisan un seguimiento cl&#237;nico y anal&#237;tico riguroso para evaluaci&#243;n por parte del equipo de salud.</p>
      <p>El presente estudio verific&#243; que el 64% y el 54% de esa poblaci&#243;n atendida en el ambulatorio de anticoagulante ten&#237;an conocimiento adecuado con INR fuera el intervalo y con INT dentro del intervalo terap&#233;utico, respectivamente. Hallazgos similares fueron descritos en un estudio que evalu&#243; el impacto de la adhesi&#243;n, del conocimiento y de la calidad de vida en el control del anticoagulante oral. Los resultados encontrados relatan que conocimiento sobre la terap&#233;utica no est&#225; asociado al control adecuado de los niveles de anticoagulaci&#243;n<sup>6</sup>, aunque se esperase lo contrario, con todo, nuestro estudio confirm&#243; estos hallazgos. Un estudio actual de cohorte prospectiva realizada en tres cl&#237;nicas especializadas de Pensilvania, con el objetivo de determinar los efectos de la adhesi&#243;n sobre el control de la anticoagulaci&#243;n, demostr&#243; en sus hallazgos que la baja adhesi&#243;n es potencialmente el origen del control ineficiente de la anticoagulaci&#243;n. Esto refuerza el hecho de que, incluso los pacientes que recibieron educaci&#243;n sobre la importancia de la adhesi&#243;n a la terap&#233;utica presentaron dificultades para mantener un buen control de la anticoagulaci&#243;n<sup>13</sup>. </p>
      <p>Otro estudio retrospectivo realizado por Nakkar et al<sup>14</sup> evalu&#243; el manejo con anticoagulante oral en 82 pacientes y evidenci&#243; que el promedio de uso de esa terap&#233;utica fue de 17 a&#241;os. De la muestra estudiada, el 19,5% presentaron, durante el tratamiento, alg&#250;n evento adverso, y el 73% presentaron INR fuera del intervalo terap&#233;utico, resaltando la importancia de programas de educaci&#243;n para esta poblaci&#243;n de pacientes, as&#237; como la necesidad de protocolos asistenciales para normalizar esta terap&#233;utica entre los profesionales de la salud. Mantener esta terap&#233;utica a largo plazo es una dura tarea, tanto para el equipo de salud como para el paciente. Insucesos tienden a elevar la morbilidad y mortalidad, lo que hace cada vez m&#225;s significativa la preocupaci&#243;n con el manejo de la terap&#233;utica empleada, que es onerosa para el sistema p&#250;blico de salud<sup>14,15</sup>. </p>
      <p>El anticoagulante m&#225;s empleado fue la fenprocumona, con un tiempo promedio de uso entre 2 y 6 a&#241;os, siendo la fibrilaci&#243;n atrial la principal indicaci&#243;n. No ocurri&#243; ning&#250;n evento tromb&#243;tico o hemorr&#225;gico significativo.</p>
      <p>Al evaluar la percepci&#243;n de los pacientes con relaci&#243;n a la terap&#233;utica empleada, el promedio del score fue de 67,8 &#177; 12,8. Verificamos que las principales preocupaciones comprendidas como limitantes fueron el uso diario de las medicaciones por un largo per&#237;odo de tiempo, los efectos adversos de la droga y la necesidad de realizaci&#243;n peri&#243;dica de ex&#225;menes de sangre; estos factores pueden contribuir para el abandono del tratamiento. Datos similares en la bibliograf&#237;a indican que la dosis &#250;nica ayuda a mejorar los niveles de adhesi&#243;n a los medicamentos<sup>16</sup>.</p>
      <p>De acuerdo con el estudio realizado por Grinberg<sup>17</sup>, con el prop&#243;sito de verificar estrategias de adhesi&#243;n a la anticoagulaci&#243;n oral, la comprensi&#243;n ineficaz del tratamiento propuesto es el principal responsable por el bajo control de enfermedades cr&#243;nicas y eventos adversos, adem&#225;s de condiciones socioecon&#243;micas, tales como ingreso, escolaridad, costo con transporte y medicaciones que implican la continuidad de la terap&#233;utica.</p>
      <p>A fin de evaluar en qu&#233; contexto de las orientaciones ocurren m&#225;s deficiencias, dividimos las dificultades de adhesi&#243;n en aspectos socioecon&#243;micos, nivel cognitivo, aspectos emocionales y fisiol&#243;gicos. Nuestros hallazgos muestran que la dificultad de adhesi&#243;n encontrada en los pacientes dentro del intervalo terap&#233;utico fue del 38,6% con relaci&#243;n al nivel cognitivo, y del 69,2% en lo que se refiere a los aspectos emocionales y psicol&#243;gicos en los pacientes fuera del intervalo terap&#233;utico preconizado. Estos resultados sugieren que hay lagunas entre lo que se orienta a los pacientes y lo que &#233;stos realmente absorben de informaciones.</p>
      <p>Vale recordar que existen diversos m&#233;todos de medida de la adhesi&#243;n al tratamiento medicamentoso, y todos ellos con ventajas y desventajas; ninguno de ellos es considerado patr&#243;n oro. Entre los m&#233;todos m&#225;s utilizados se destacan los clasificados por algunos autores<sup>17</sup> como directos e indirectos. Los m&#233;todos directos se basan en t&#233;cnicas anal&#237;ticas que verifican si el medicamento fue administrado en la dosis y en la frecuencia necesaria, por medio de marcadores qu&#237;micos de mayor permanencia en el organismo. La medida del nivel s&#233;rico de la droga presenta mayor exactitud, sin embargo su costo es elevado, adem&#225;s de ser un procedimiento invasivo. El monitoreo electr&#243;nico de apertura del envase tambi&#233;n es efectivo, pero su costo tambi&#233;n es alto. Los m&#233;todos indirectos incluyen entrevistas estructuradas, donaciones de medicamentos para los pacientes y conteo de comprimidos que sobraron en las consultas de retorno. Procedimientos muy utilizados en ensayos cl&#237;nicos, sin embargo, est&#225;n sujetos a manipulaci&#243;n por parte del individuo, y tampoco inspiran fidedignidad.</p>
      <p>Investigaciones realizadas en el mundo entero han demostrado la importancia de investigaciones relacionadas a la adhesi&#243;n al tratamiento medicamentoso y a los cambios de estilo de vida de los pacientes en uso de anticoagulante oral. Autores destaca que la calidad del control terap&#233;utico para mantener los niveles ideales de INR y la adhesi&#243;n a la terap&#233;utica es baja, a causa de la carencia y/o fallas en los protocolos existentes y en raz&#243;n de la no existencia de equipos de salud especializados para realizar programas educacionales<sup>18,19</sup>. La comprensi&#243;n de factores determinantes de la terap&#233;utica, as&#237; como la correcta forma de tomar las medicaciones, la prevenci&#243;n e identificaci&#243;n de los principales eventos adversos y la interacci&#243;n entre droga y dieta remiten al &#233;xito del tratamiento, hacen posible la adhesi&#243;n y el alcance de los niveles ideales de anticoagulaci&#243;n y reducen la morbilidad y mortalidad en pacientes con terapia de largo plazo<sup>3,20</sup>.</p>
      <p>El pron&#243;stico de pacientes en uso de anticoagulante oral depende no s&#243;lo de la terap&#233;utica farmacol&#243;gica, como tambi&#233;n de aspectos no farmacol&#243;gicos fundamentales para el tratamiento. Los pacientes necesitan seguimiento constante para recibir orientaciones a respecto del autocuidado, de la posibilidad de evento tromboemb&#243;lico y de maneras de adaptaci&#243;n a la terap&#233;utica empleada. La educaci&#243;n en salud es una de las atribuciones de los equipos que trabajan con esta poblaci&#243;n de pacientes, para ello es necesario que los profesionales desarrollen nuevas estrat&#233;gicas buscando mejorar la adhesi&#243;n a la terap&#233;utica. </p>
      <p>
        <bold>Conclusiones </bold>
      </p>
      <p>Los resultados de este estudio no muestran asociaci&#243;n entre las variables analizadas en los subgrupos dentro y fuera del intervalo terap&#233;utico, evaluado por el INR. No obstante, a pesar de la prevalencia de pacientes en uso de anticoagulante oral con INR dentro de los valores preconizados, todav&#237;a hay una buena parte de pacientes que no adhieren a la terap&#233;utica. El desarrollo de nuevas investigaciones, como estudios aleatorios, con estrategias sistem&#225;ticas de educaci&#243;n acerca de medidas terap&#233;uticas no farmacol&#243;gicas, es fundamental para buscar m&#225;s evidencias sobre los problemas identificados y tambi&#233;n para el desarrollo de protocolos asistenciales que identifiquen la no adhesi&#243;n, con miras a minimizar las complicaciones y llenar las lagunas referentes al uso continuo de anticoagulante oral.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de la tesis de Monograf&#237;a de Residencia Integrada en Salud de Francieli Giachini Esm&#233;rio del Instituto de Cardiolog&#237;a de Rio Grande do Sul / Fundaci&#243;n Universitaria de Cardiolog&#237;a.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Constant use of oral anticoagulants: implications in the control of their adequate levels</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Inappropriate and subtherapeutic anticoagulants dosages may result in severe thromboembolic and bleeding complications. The use of this treatment requires special attention and strict clinical and laboratory follow-up. OBJECTIVE: To identify factors associated with appropriate control of the oral anticoagulant use, assessing the patients' knowledge and perception of the treatment. METHODS: A cross-sectional study which included 140 patients followed in the oral anticoagulation outpatient clinic from November 2005 to June 2006. A structured questionnaire was drafted and applied to obtain the clinical characteristics of the patients and their knowledge about the treatment, their compliance with the treatment (Morisky&#180;s test) and their perception of the treatment. RESULTS: The main indications for the use of oral anticoagulation therapy were atrial fibrillation (61.4%) and a prosthetic heart valve (55%). The duration of anticoagulation ranged from 24 to 72 months, and phenprocoumon (58%) was the most commonly used anticoagulant. As to the perception of the treatment, 95% of the patients mentioned concern about daily use of this medication. Periodic blood tests (21.4%) and the strict intake of oral anticoagulant (12.8%) were considered limiting factors. Adequate knowledge was outstanding in patients with an international normalized ratio (INR) outside the therapeutic range (64%), compared to patients with an INR within the therapeutic range (62%), as well as compliance with treatment in patients with an INR within the therapeutic range (54%), but with no statistical significance. CONCLUSION: The results of this study show a prevalence of patients using oral anticoagulant with an INR within optimal values, although a high percentage of patients do not comply with the treatment. In this population it is clearly seen that they do not fully understand the treatment.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Anticoagulants</kwd>
        <kwd>drug utilization</kwd>
        <kwd>drug control</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="txt-body3">
          <label>
            <bold>Constant use of oral anticoagulants: implications in the control of their adequate levels</bold>
          </label>
          <p>
            <bold>Francieli Giachini Esmerio; Emiliane Nogueira Souza; Tiago Luz Leiria; Rosana Lunelli; Maria Antonieta Moraes</bold>
          </p>
        </fn>
      </p>
      <p>Instituto de Cardiologia do Rio Grande do Sul, da Funda&#231;&#227;o Universit&#225;ria de Cardiologia (IC/FUC), Porto Alegre, RS - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold> BACKGROUND: </bold>Inappropriate and subtherapeutic anticoagulants dosages may result in severe thromboembolic and bleeding complications. The use of this treatment requires special attention and strict clinical and laboratory follow-up.</p>
      <p><bold>OBJECTIVE:</bold> To identify factors associated with appropriate control of the oral anticoagulant use, assessing the patients' knowledge and perception of the treatment.</p>
      <p><bold>METHODS:</bold> A cross-sectional study which included 140 patients followed in the oral anticoagulation outpatient clinic from November 2005 to June 2006. A structured questionnaire was drafted and applied to obtain the clinical characteristics of the patients and their knowledge about the treatment, their compliance with the treatment (Morisky&#180;s test) and their perception of the treatment.</p>
      <p><bold>RESULTS: </bold>The main indications for the use of oral anticoagulation therapy were atrial fibrillation (61.4%) and a prosthetic heart valve (55%). The duration of anticoagulation ranged from 24 to 72 months, and phenprocoumon (58%) was the most commonly used anticoagulant. As to the perception of the treatment, 95% of the patients mentioned concern about daily use of this medication. Periodic blood tests (21.4%) and the strict intake of oral anticoagulant (12.8%) were considered limiting factors. Adequate knowledge was outstanding in patients with an international normalized ratio (INR) outside the therapeutic range (64%), compared to patients with an INR within the therapeutic range (62%), as well as compliance with treatment in patients with an INR within the therapeutic range (54%), but with no statistical significance.</p>
      <p><bold>CONCLUSION:</bold> The results of this study show a prevalence of patients using oral anticoagulant with an INR within optimal values, although a high percentage of patients do not comply with the treatment. In this population it is clearly seen that they do not fully understand the treatment. </p>
      <p><bold>Key words: </bold>Anticoagulants; drug utilization; drug control.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Although the use of oral anticoagulants is effective, there are risks associated with it. Annual risk estimates range from 2 to 8% for bleeding, and 1 to 3% for treatment failure. Therefore, it is important to decide the appropriate moment to initiate the treatment or modify the dosage of the medication<sup>1</sup>. The use of these medications requires special control and strict clinical and laboratory follow-up by a multidisciplinary team due to bleeding complications. The use of oral anticoagulation therapy is considered as a safety factor for the patient, but the health care team needs to pay more attention to the issue of adherence to the medication. Poor compliance with the prescribed medication and consequently with the proposed clinical treatment has a negative impact on all aspects of health care, engenders excessive costs, and results in the sub-utilization of available treatment resources, as well as serious consequences to patients and an increase in adverse events in chronic diseases. </p>
      <p>Sawicki<sup>2 </sup>and Newall et al<sup>3</sup> described in their studies a patient education program on self-adjustment and management of oral anticoagulants, where the risk of any complication depends on the duration of medication use and the strictness of the INR control, achieved by frequent laboratory tests for dosage adjustment. Samsa et al<sup>4 </sup>and Hirsh et al<sup>5</sup> stressed that, for patients with a prosthetic heart valve, the maintenance of long-term anticoagulation means adherence to a medication regimen during the patient's entire life. </p>
      <p>Several studies<sup>6-8</sup> have demonstrated the existence of factors that interfere in the control of anticoagulation levels, including socio-economic factors; physiological factors; psychological factors and emotional factors.</p>
      <p>According to the World Health Organization<sup>9</sup>, poor adherence to medication use is currently one of the great challenges for the improvement in world health status. These conclusions demonstrate a need for further enlightenment about the medication use by the team assigned to treat this group of patients. In this context, the objective of this study was to identify factors associated with an adequate control of oral anticoagulant levels, assessing the patients' knowledge and perception of the therapy used.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>This was a cross-sectional study which included patients followed in the oral anticoagulation outpatient clinic, at a cardiology hospital in the State of Rio Grande do Sul, from November 2005 to June 2006. In the oral anticoagulation outpatient clinic, patients are regularly tested for laboratory control of INR, and approximately 1200 patients are seen each month. Patients eligible for this study were &#8805;18 years old, were using oral anticoagulants, and agreed to answer the research questions.</p>
      <p>A questionnaire was drawn, containing questions about clinical and demographic characteristics, adherence to treatment, knowledge about the therapy and the patient's perception of the oral anticoagulant use. To evaluate adherence to therapy, we used the Morisky test<sup>7</sup>, which is a validated instrument that is applicable to different types of medication therapy. This test consists of four objective questions, used as a standardized evaluation, to assess the behavioral pattern of the patient regarding daily use of the prescribed medication. The questions address intake timing, missing doses, symptoms and side effects. The questionnaire rates the patient's adherence according to the number of correct answers. We took into account INR within the therapeutic range and INR outside the therapeutic range, with an average of five INR measurements for each patient. To analyze the patient's knowledge about oral anticoagulant use, two questions were formulated about the objective of the therapy and its main adverse effect. The ability to correctly answer both questions was considered an adequate knowledge. To identify the patients' perception of oral anticoagulant use, six questions were graduated in a score ranging from 1 to 100 points, and an ordinal number was assigned to each answer, beginning from the number 1, which corresponds to the worst perception of the therapy. </p>
      <p>To study the difficulties with adherence to therapy, we took into account the patients' oral report and the examiner's perception. We evaluated socio-economic aspects, such as age, schooling, transportation expenses and medication used; physiological aspects, such as drug interactions, multiple medication use, diet restrictions, associated diseases and physical handicaps; and emotional aspects, such as denial of the disease, history of depression, personal problems; and cognition level, taking into account the patients' ability to understand, apply, analyze and sum up their personal health status<sup>10</sup>. </p>
      <p>This project was submitted to and approved by the Research Ethics Committee of the institution, and all patients signed an informed consent document. Categorical variables were described through absolute and relative frequencies, and continuous variables were described as mean and standard deviation or median and interquartile interval (25<sup>th</sup> and 75<sup>th</sup> percentile), depending on whether or not they followed a normal distribution. To compare the categorical variables, we used Pearson's chi-square test, with continuity correction when necessary. To compare the means between the groups, we used Student's t-test, depending on whether or not the parametric assumptions were followed. We used a significance level of &#945; = 0.05.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Clinical and demographic characteristics</bold>
      </p>
      <p>140 patients (mean age 60&#177;11.5) using oral anticoagulants were included in the study. The main indication for the use of this medication therapy was atrial fibrilation (61.4%), followed by a prosthetic heart valve (55%). The anticoagulants used in this population were phenprocoumon (58%) and warfarin (42%), with a duration of use ranging from 24 to 72 months. The most prevalent associated comorbities were elevated high blood pressure (69.3%) and diabetes mellitus (26.4%). These results are shown in <xref ref-type="table" rid="tab01-body3">table 1</xref>.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Questions about perception of the therapy</bold>
      </p>
      <p>To identify the patient's perception of oral anticoagulant use, six questions were graduated in a score ranging from 0 to 100 points. Our results showed that the mean score was 67.8&#177;12.8. We observed that 95% of the patients mentioned concern about daily use of the medication, while 68% expressed insecurity regarding the possibility of bleeding. Our findings showed that bleeding occurred in 32.8% of the patients, and there were no thrombotic events. The questions showed that the patients considered the need of periodic blood tests (21.4%) and the strict intake of oral anticoagulants (12.8%) as limiting factors. These results are shown in <xref ref-type="table" rid="tab02-body3">table 2</xref>.</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt02-en.jpg"/></table-wrap>
      <p>
        <bold>INR within and outside the therapeutical range </bold>
      </p>
      <p>A comparison between patients with an INR within the therapeutical range and patients with an INR outside the therapeutical range showed that the knowledge about the therapy and the adherence to oral anticoagulation therapy were almost the same in both groups. There was a slight prevalence of proper knowledge among patients with an INR outside the therapeutical range (64%) and of adherence among patients with an INR within the therapeutical range (54%), but with no statistically significant difference between these results.</p>
      <p>As to the main indications for the use of anticoagulants, there was a prevalence of patients with atrial fibrilation and an INR within the therapeutical range, as well as patients with a prosthetic heart valve and an INR outside the therapeutical range. We observed that there were more patients within the therapeutical range using phenprocoumon (62%), in comparison to those using warfarin (38%). The cognition level (38.5%), in the group within the therapeutical range, and the emotional and psychological aspects (69.2%), in the group outside the therapeutical range, were the factors that had greater impact on non-adherence. These data are shown in <xref ref-type="table" rid="tab03-body3">table 3</xref>.</p>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0549-00017-gt03-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In the last few years, the use of oral anticoagulation therapy in clinical cardiology had more indications and was validated by several clinical studies<sup>11,12</sup>. Although oral anticoagulants are clinically indicated to prevent thromboembolic events, inappropriate and subtherapeutic dosages to maintain the INR may result in serious thromboembolic complications. Patients using this therapy have specific needs and require special attention, and consequently need strict clinical and laboratory follow-up by health care teams.</p>
      <p>This study demonstrated, in the population followed in the oral anticoagulation outpatient clinic, an adequate knowledge about the therapy in 64% (INR outside the therapeutical range) and 54% (INR within the therapeutical range) of the patients. Similar findings were described in a study that evaluated the impact of adherence to the treatment, knowledge about the therapy and quality of life on the control of oral anticoagulation therapy. The results indicated that the knowledge about the therapy was not associated with an adequate control of oral anticoagulant levels<sup>6</sup>, although the opposite was expected. However, our study confirmed those findings. A recent prospective cohort study performed at 3 specialized clinics in Pennsylvania, to determine the effect of adherence on anticoagulation control, demonstrated that poor adherence is potentially a major source of poor anticoagulation control. The authors stressed that although patients received education about the importance of adherence to therapy, they still had difficulties maintaining adequate anticoagulation control<sup>13</sup>. </p>
      <p>Another retrospective study carried out by Nakkar et al<sup>14</sup>, evaluated the management of oral anticoagulants in 82 patients, indicating that the mean duration of anticoagulation was 17 years, and 19.5% of the patients had treatment-related complications, and 73% had an INR outside therapeutic range, stressing the importance of educational programs for this population of patients, as well as the need for care guidelines to standardize this therapy among health care professionals. Long-term maintenance of this therapy is hard work, both for health care professionals and the patient. Failures tend to increase morbity and mortality, increasing the seriousness of the apprehension about therapy management, which raises costs for the public health care system<sup>14,15</sup>. </p>
      <p>The most used anticoagulant was phenprocoumon, with the mean duration of anticoagulation ranging from 2 to 6 years, and its main indication was atrial fibrilation. No significative thromboembolic or bleeding event occurred.</p>
      <p>In regard to patients' perception of the therapy, the mean score was 67.8&#177;12.8. We observed that the main concerns considered as limiting factors were prolonged daily use of the medication, adverse effects of the medication and the need of periodic blood tests, factors which may contribute to abandonment of therapy. Similar data in the literature indicate that once-a-day dosing helps improve medication adherence rates<sup>16</sup>. </p>
      <p>A study performed by Grinberg<sup>17</sup>, to investigate strategies for oral anticoagulant adherence, reported that poor knowledge about the treatment is the main source of poor control of chronic diseases and adverse effects, as well as socio-economic aspects, such as earnings, schooling, transportation expenses, and the use of medication that requires continuous therapy.</p>
      <p>Aiming at evaluating the context in which most problems occur, we divided adherence difficulties into four categories: socio-economic aspects, cognition level, emotional aspects, and physiological aspects. Our findings demonstrated that adherence difficulties were related to cognition level in 38.6% of the patients within the therapeutic range, and to emotional and psychological aspects, in 69.2% of patients outside the therapeutic range. These results suggest that there is a gap between the information provided to the patients and their understanding of the information conveyed.</p>
      <p>It's worth remembering that there are several methods for evaluating adherence to medication treatment, all with advantages and disadvantages, and none of them is considered a golden standard. Among the most used methods, those classified by some authors<sup>17</sup> as direct and indirect stand out. Direct methods are based on analytical techniques that investigate if the medication was administered in the required dosage and frequency, using chemical markers which are not rapidly cleared from the body, and the measurement of the serum levels of the drug, which is more accurate but, not only highly expensive, but also an invasive method. Electronic monitoring of medication case opening is effective, but also very expensive. Indirect methods include structured interviews and tablet counting, frequently used in clinical assays in which patients are provided with medication, but they can be easily altered, and therefore are not very reliable. </p>
      <p>Several studies the world over have demonstrated the importance of research on adherence to medication and the change in lifestyle required of patients using oral anticoagulants. The authors stressed that therapeutic quality control to maintain optimal levels of INR and therapy adherence were poor, due to a lack of and/or failure in current guidelines and the absence of health care teams who are specialized in educational programs<sup>18,19</sup>. The knowledge about decisive factors in therapy, such as the proper way to take the medication, the prevention and identification of main adverse effects, and drug and diet interactions, determine the success of the treatment and make adherence to therapy and the maintenance of optimal levels of anticoagulation possible, consequently reducing the morbity and mortality of long-term therapy patients<sup>3,20</sup>.</p>
      <p>The prognosis of patients using oral anticoagulants depends not only on the pharmacological therapy, but also on some non-pharmacological elements that are vital for the treatment. They need constant follow-up and continuing education on self-care measures, potential thromboembolic events and adaptation to the therapy. Health education is one of the charges of those who work with this population of patients, and these professionals need to develop new strategies to improve adherence to therapy. </p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>The results of this study did not demonstrate the existence of an association of the analyzed variables in the subgroup with an INR within the therapeutical range compared to the subgroup with an INR outside the therapeutical range. However, despite the prevalence of patients using oral anticoagulants with an INR within the prescribed values, there are still a large number of patients who do not comply with the treatment. Further research, such as randomized studies, with systematic strategies for patient education on non-pharmacological therapies, is vital for the search of more evidence about the identified problems and also for the development of care guidelines that may identify non-adherence, in order to drastically reduce complications and fill the gap on the issue of continuous use of oral anticoagulants.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis: Monograph of Integrated Residency in Health, submitted by Francieli Giachini Esm&#233;rio, from Cardiologia do Rio Grande do Sul / Funda&#231;&#227;o Universit&#225;ria de Cardiologia.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
